“…Immune tolerance and anti-inflammatory properties—UC-MSCs exert immunomodulation properties [ 163 , 175 , 176 ], even related to the expression and release of specific factors, such as the nonclassical HLA class I antigen, HLA-G [ 157 , 177 ], HLA-E, CD276/B7-H3, leukemia inhibitory factor (LIF), indolamine 2,3-dioxygenase-1 (IDO-1), galectin-1 (Gal-1), and heat shock protein 10/Early Pregnancy Factor (HSP10/EPF), being able to modulate or inhibit lymphocyte proliferation [ 175 ]. These factors are involved in tolerogenic processes occurring at the fetal–maternal interface [ 178 , 179 , 180 , 181 , 182 , 183 ], permitting, in turn, the semi-allogeneic embryo to escape surveillance of the maternal immune system. Specifically, HLA-G is an inhibitory molecule involved in immune tolerance and exerts its inhibitory functions interacting with inhibitory receptors Ig-like transcript (ILT) receptors, such as ILT-2, ILT-3, and ILT-4, and killer cell immunoglobulin-like receptor (KIR), two Ig domains, and long cytoplasmic tail 4, KIR2DL4, differentially expressed by NK, T, and antigen-presenting cells [ 184 , 185 ].…”